MedTrace Logo

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.

Conditions

  • Cocaine Abuse and Dependence

Interventions

DRUG

Donepezil, 5 mg daily

This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.

OTHER

Oral Placebo

Inactive Comparator with Similar Appearance to Active Medication

Sponsors & Collaborators

Principal Investigators

  • Kenneth Grasing, MD · VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467389 on ClinicalTrials.gov